abstract objectives: previous research has demonstrated that patients with prostate cancer participating in the prostate cancer lifestyle trial had a reduction in prostate-specific antigen (psa) levels, inhibition of lncap cell growth, and fewer prostate cancer-related clinical events at the end of 1 year compared with controls.